NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
Clinical Trials
4 trialsNCT01320280 2022-07-01
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT00875433 2013-12-30
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Boehringer Ingelheim
Phase 2 Completed